AAAAAA
Results: 1-25/32
Authors:
HENRY K
ERICE A
TIERNEY C
BALFOUR HH
FISCHL MA
KMACK A
LIOU SH
KENTON A
HIRSCH MS
PHAIR J
MARTINEZ A
KAHN JO
Citation: K. Henry et al., A RANDOMIZED, CONTROLLED, DOUBLE-BLIND-STUDY COMPARING THE SURVIVAL BENEFIT OF 4 DIFFERENT REVERSE-TRANSCRIPTASE INHIBITOR THERAPIES (3-DRUG, 2-DRUG, AND ALTERNATING DRUG) FOR THE TREATMENT OF ADVANCED AIDS, Journal of acquired immune deficiency syndromes and human retrovirology, 19(4), 1998, pp. 339-349
Authors:
ANWAR F
ERICE A
LI WY
JESSURUN J
Citation: F. Anwar et al., ARE THERE CYTOPATHIC FEATURES ASSOCIATED WITH INFECTION CAUSED BY ANTIVIRAL-RESISTANT CYTOMEGALOVIRUS, Modern pathology, 11(1), 1998, pp. 143-143
Authors:
DEMETER LM
DAQUILA R
WEISLOW O
LORENZO E
ERICE A
FITZGIBBON J
SHAFER R
RICHMAN D
HOWARD TM
ZHAO YQ
FISHER E
HUANG D
MAYERS D
SYLVESTER S
ARENS M
SANNERUD K
RASHEED S
JOHNSON V
KURITZKES D
REICHELDERFER P
JAPOUR A
Citation: Lm. Demeter et al., INTERLABORATORY CONCORDANCE OF DNA-SEQUENCE ANALYSIS TO DETECT REVERSE-TRANSCRIPTASE MUTATIONS IN HIV-1 PROVIRAL DNA, Journal of virological methods, 75(1), 1998, pp. 93-104
Authors:
GAUDREAU A
HILL E
BALFOUR HH
ERICE A
BOIVIN G
Citation: A. Gaudreau et al., PHENOTYPIC AND GENOTYPIC CHARACTERIZATION OF ACYCLOVIR-RESISTANT HERPES-SIMPLEX VIRUSES FROM IMMUNOCOMPROMISED PATIENTS, The Journal of infectious diseases, 178(2), 1998, pp. 297-303
Authors:
ERICE A
BORRELL N
LI WY
MILLER WJ
BALFOUR HH
Citation: A. Erice et al., GANCICLOVIR SUSCEPTIBILITIES AND ANALYSIS OF UL97 REGION IN CYTOMEGALOVIRUS (CMV) ISOLATES FROM BONE-MARROW RECIPIENTS WITH CMV DISEASE AFTER ANTIVIRAL PROPHYLAXIS, The Journal of infectious diseases, 178(2), 1998, pp. 531-534
Authors:
ERICE A
BALFOUR HH
Citation: A. Erice et Hh. Balfour, INTERPRETING HUMAN CYTOMEGALOVIRUS ANTIVIRAL DRUG SUSCEPTIBILITY TESTING - THE ROLE OF MIXED VIRUS POPULATIONS - REPLY, The Journal of infectious diseases, 177(3), 1998, pp. 823-824
Authors:
FLETCHER CV
ACOSTA EP
HENRY K
PAGE LM
GROSS CR
KAWLE SP
REMMEL RP
ERICE A
BALFOUR HH
Citation: Cv. Fletcher et al., CONCENTRATION-CONTROLLED ZIDOVUDINE THERAPY, Clinical pharmacology and therapeutics, 64(3), 1998, pp. 331-338
Authors:
ERICE A
GRYS T
BALFOUR H
BELL J
BELL E
Citation: A. Erice et al., MUTATIONS IN CYTOMEGALOVIRUS UL97 AND DNA-POLYMERASE - STRUCTURAL MODELS OF THE EFFECTS ON DRUG-RESISTANCE, The FASEB journal, 11(9), 1997, pp. 3404-3404
Authors:
ACOSTA EP
HENRY K
PAGE LM
ERICE A
BALFOUR HH
FLETCHER CV
Citation: Ep. Acosta et al., PHARMACOKINETICS AND SAFETY OF CONCENTRATION-CONTROLLED ORAL ZIDOVUDINE THERAPY, Pharmacotherapy, 17(3), 1997, pp. 424-430
Authors:
MARSCHNER IC
MAYERS DL
ERICE A
SMEATON L
JOHNSON VA
RICHMAN DD
REICHELDERFER P
JAPOUR AJ
Citation: Ic. Marschner et al., STANDARDIZED PERIPHERAL-BLOOD MONONUCLEAR CELL-CULTURE ASSAY FOR ZIDOVUDINE SUSCEPTIBILITY TESTING OF CLINICAL HUMAN-IMMUNODEFICIENCY-VIRUSTYPE-1 ISOLATES - EFFECT OF REDUCING THE NUMBERS OF REPLICATES AND CONCENTRATIONS, Journal of clinical microbiology, 35(3), 1997, pp. 756-758
Authors:
ERICE A
GILRODA C
PEREZ JL
BALFOUR HH
SANNERUD KJ
HANSON MN
BOIVIN G
CHOU SW
Citation: A. Erice et al., ANTIVIRAL SUSCEPTIBILITIES AND ANALYSIS OF UL97 AND DNA-POLYMERASE SEQUENCES OF CLINICAL CYTOMEGALOVIRUS ISOLATES FROM IMMUNOCOMPROMISED PATIENTS, The Journal of infectious diseases, 175(5), 1997, pp. 1087-1092
Authors:
HUGHES MD
JOHNSON VA
HIRSCH MS
BREMER JW
ELBEIK T
ERICE A
KURITZKES DR
SCOTT WA
SPECTOR SA
BASGOZ N
FISCHL MA
DAQUILA RT
Citation: Md. Hughes et al., MONITORING PLASMA HIV-1 RNA LEVELS IN ADDITION TO CD4(+) LYMPHOCYTE COUNT IMPROVES ASSESSMENT OF ANTIRETROVIRAL THERAPEUTIC RESPONSE, Annals of internal medicine, 126(12), 1997, pp. 929-938
Authors:
JAPOUR AJ
LERTORA JJ
MEEHAN PM
ERICE A
CONNOR JD
GRIFFITH BP
CLAX PA
HOLDENWILTSE J
HUSSEY S
WALESKY M
COONEY E
POLLARD R
TIMPONE J
MCLAREN C
JOHANNESON N
WOOD K
BOOTH DK
BASSIAKOS Y
CRUMPACKER CS
Citation: Aj. Japour et al., A PHASE-I STUDY OF THE SAFETY, PHARMACOKINETICS, AND ANTIVIRAL ACTIVITY OF COMBINATION DIDANOSINE AND RIBAVIRIN IN PATIENTS WITH HIV-1 DISEASE, Journal of acquired immune deficiency syndromes and human retrovirology, 13(3), 1996, pp. 235-246
Authors:
FAUST RA
HENRY K
DAILEY P
MELROE H
SULLIVAN C
ERICE A
HAASE AT
BOIES LR
Citation: Ra. Faust et al., OUTPATIENT BIOPSIES OF THE PALATINE TONSIL - ACCESS TO LYMPHOID-TISSUE FOR ASSESSMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS RNA TITERS, Otolaryngology and head and neck surgery, 114(4), 1996, pp. 593-598
Authors:
SHAFER RW
WINTERS MA
MAYERS DL
JAPOUR AJ
KURITZKES DR
WEISLOW OS
WHITE F
ERICE A
SANNERUD KJ
IVERSEN A
PENA F
DIMITROV D
FRENKEL LM
REICHELDERFER PS
Citation: Rw. Shafer et al., INTERLABORATORY COMPARISON OF SEQUENCE-SPECIFIC PCR AND LIGASE DETECTION REACTION TO DETECT A HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 DRUG-RESISTANCE MUTATION, Journal of clinical microbiology, 34(7), 1996, pp. 1849-1853
Authors:
BALFOUR HH
FLETCHER CV
ERICE A
HENRY WK
ACOSTA EP
SMITH SA
HOLM MA
BOIVIN G
SHEPP DH
CRUMPACKER CS
EATON CA
MARTINMUNLEY SS
Citation: Hh. Balfour et al., EFFECT OF FOSCARNET ON QUANTITIES OF CYTOMEGALOVIRUS AND HUMAN-IMMUNODEFICIENCY-VIRUS IN BLOOD OF PERSONS WITH AIDS, Antimicrobial agents and chemotherapy, 40(12), 1996, pp. 2721-2726
Authors:
BOIVIN G
CHOU SW
QUIRK MR
ERICE A
JORDAN MC
Citation: G. Boivin et al., DETECTION OF GANCICLOVIR RESISTANCE MUTATIONS AND QUANTITATION OF CYTOMEGALOVIRUS (CMV) DNA IN LEUKOCYTES OF PATIENTS WITH FATAL DISSEMINATED CMV DISEASE, The Journal of infectious diseases, 173(3), 1996, pp. 523-528
Authors:
CAVERT W
COOMBS RW
GRIMES J
KURITZKES D
JOHNSON V
KAPPES J
STEIN D
BEATTY C
ERICE A
WINTERS M
KATZENSTEIN D
JOHNSON E
ROJO E
MIRABILE M
ELBEIK T
TSIATIS B
COREY L
Citation: W. Cavert et al., THERAPEUTIC SIGNIFICANCE OF SWITCHING TO DIDANOSINE (DDI) OR ADDING DDI IN SUBJECTS WITH ZIDOVUIDINE-RESISTANT HIV-1, Journal of acquired immune deficiency syndromes and human retrovirology, 10, 1995, pp. 41-41
Authors:
ERICE A
HOLM MA
SANJUAN MV
DUNN DL
GILL PC
BALFOUR HH
Citation: A. Erice et al., EVALUATION OF CMV-VUE ANTIGENEMIA ASSAY FOR RAPID DETECTION OF CYTOMEGALOVIRUS IN MIXED-LEUKOCYTE BLOOD FRACTIONS, Journal of clinical microbiology, 33(4), 1995, pp. 1014-1015
Authors:
HANSON MN
PREHEIM LC
CHOU SW
TALARICO CL
BIRON KK
ERICE A
Citation: Mn. Hanson et al., NOVEL MUTATION IN THE UL97 GENE OF A CLINICAL CYTOMEGALOVIRUS STRAIN CONFERRING RESISTANCE TO GANCICLOVIR, Antimicrobial agents and chemotherapy, 39(5), 1995, pp. 1204-1205
Authors:
HAVLIR D
CHEESEMAN SH
MCLAUGHLIN M
MURPHY R
ERICE A
SPECTOR SA
GREENOUGH TC
SULLIVAN JL
HALL D
MYERS M
LAMSON M
RICHMAN DD
Citation: D. Havlir et al., HIGH-DOSE NEVIRAPINE - SAFETY, PHARMACOKINETICS, AND ANTIVIRAL EFFECTIN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION, The Journal of infectious diseases, 171(3), 1995, pp. 537-545
Authors:
CHOU SW
ERICE A
JORDAN MC
VERCELLOTTI GM
MICHELS KR
TALARICO CL
STANAT SC
BIRON KK
Citation: Sw. Chou et al., ANALYSIS OF THE UL97 PHOSPHOTRANSFERASE CODING SEQUENCE IN CLINICAL CYTOMEGALOVIRUS ISOLATES AND IDENTIFICATION OF MUTATIONS CONFERRING GANCICLOVIR RESISTANCE, The Journal of infectious diseases, 171(3), 1995, pp. 576-583
Authors:
ERICE A
BALFOUR HH
Citation: A. Erice et Hh. Balfour, RESISTANCE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TO ANTIRETROVIRAL AGENTS - A REVIEW, Clinical infectious diseases, 18(2), 1994, pp. 149-156
Authors:
BALFOUR HH
BENSON C
BRAUN T
CASSENS B
ERICE A
FRIEDMANKIEN A
KLEIN T
POLSKY B
SAFRIN S
Citation: Hh. Balfour et al., MANAGEMENT OF ACYCLOVIR-RESISTANT HERPES-SIMPLEX AND VARICELLA-ZOSTERVIRUS-INFECTIONS, Journal of acquired immune deficiency syndromes, 7(3), 1994, pp. 254-260
Authors:
DUNN DL
GILLINGHAM KJ
KRAMER MA
SCHMIDT WJ
ERICE A
BALFOUR HH
GORES PF
GRUESSNER RWG
MATAS AJ
PAYNE WD
SUTHERLAND DER
NAJARIAN JS
Citation: Dl. Dunn et al., A PROSPECTIVE RANDOMIZED STUDY OF ACYCLOVIR VERSUS GANCICLOVIR PLUS HUMAN IMMUNE GLOBULIN PROPHYLAXIS OF CYTOMEGALOVIRUS-INFECTION AFTER SOLID-ORGAN TRANSPLANTATION, Transplantation, 57(6), 1994, pp. 876-884